GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: drug combo targets tough tumors
Disease control Not yet recruitingThis study tests a new combination of two experimental drugs (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with advanced HER2-negative stomach or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors and delay d…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 17, 2026 00:59 UTC
-
New drug duo targets tough stomach cancer before surgery
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs (Trastuzumab rezetecan and retlirafusp alfa) in 12 people with a specific type of stomach cancer that is HER2-positive and likely to respond to immunotherapy. The goal is to see if the treatment is safe and can shrink tumors…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New drug cocktail aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (lenvatinib) in 20 people with a specific type of advanced stomach cancer (MSI-H/dMMR) that might be removable with surgery. The goal is to see if thi…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New combo therapy aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis study tests whether adding low-dose radiation and an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly…
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC